Thromboxane b2

Thromboxane b2 is a lipid of Fatty Acyls (FA) class. Thromboxane b2 is associated with abnormalities such as endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia and Thrombocytosis. The involved functions are known as Platelet Activation, Excretory function, Anabolism, Inflammation and mRNA Expression. Thromboxane b2 often locates in Endothelium, Hepatic and Microsomes, Liver. The associated genes with Thromboxane b2 are PTGS2 gene, prothrombin fragment 2 and CCL14 wt Allele.

Cross Reference

Introduction

To understand associated biological information of Thromboxane b2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Thromboxane b2?

Thromboxane b2 is suspected in endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia, Thrombocytosis, Acute Coronary Syndrome and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Thromboxane b2

MeSH term MeSH ID Detail
Gastric Dilatation D013271 1 associated lipids
Latex Hypersensitivity D020315 1 associated lipids
Stomach Volvulus D013277 1 associated lipids
Foot Rot D005535 1 associated lipids
Frostbite D005627 1 associated lipids
Strongyle Infections, Equine D013319 1 associated lipids
Basal Ganglia Hemorrhage D020145 1 associated lipids
Edema, Cardiac D004489 1 associated lipids
Osteoblastoma D018215 1 associated lipids
Radiculopathy D011843 1 associated lipids
Oligomenorrhea D009839 1 associated lipids
Erythromelalgia D004916 1 associated lipids
Intracranial Hemorrhage, Hypertensive D020299 1 associated lipids
Cholecystitis, Acute D041881 1 associated lipids
Bluetongue D001819 1 associated lipids
Atrial Premature Complexes D018880 1 associated lipids
Heart Septal Defects D006343 2 associated lipids
Retinal Vein Occlusion D012170 2 associated lipids
Weil Disease D014895 2 associated lipids
Pulmonary Heart Disease D011660 2 associated lipids
Drowning D004332 2 associated lipids
Aortic Arch Syndromes D001015 2 associated lipids
Mixed Connective Tissue Disease D008947 2 associated lipids
Tachycardia, Paroxysmal D013614 2 associated lipids
Fibromuscular Dysplasia D005352 2 associated lipids
Contusions D003288 3 associated lipids
Bronchopulmonary Sequestration D001998 3 associated lipids
Airway Remodeling D056151 3 associated lipids
Angina Pectoris, Variant D000788 3 associated lipids
Jejunal Diseases D007579 3 associated lipids
Pneumonia, Viral D011024 3 associated lipids
Platelet Storage Pool Deficiency D010981 3 associated lipids
Takayasu Arteritis D013625 3 associated lipids
Tachycardia, Supraventricular D013617 3 associated lipids
Pneumonia, Aspiration D011015 3 associated lipids
Infertility D007246 3 associated lipids
Macular Edema D008269 3 associated lipids
Hydatidiform Mole D006828 3 associated lipids
Aortic Rupture D001019 3 associated lipids
Hemorrhagic Fever with Renal Syndrome D006480 3 associated lipids
Yang Deficiency D016711 3 associated lipids
Systemic Inflammatory Response Syndrome D018746 4 associated lipids
Diseases in Twins D004200 4 associated lipids
Hyperaldosteronism D006929 4 associated lipids
Glomerulosclerosis, Focal Segmental D005923 4 associated lipids
Chediak-Higashi Syndrome D002609 4 associated lipids
Chest Pain D002637 4 associated lipids
Heart Valve Diseases D006349 4 associated lipids
Streptococcal Infections D013290 4 associated lipids
Retinal Diseases D012164 4 associated lipids
Per page 10 20 50 100 | Total 293

PubChem Associated disorders and diseases

What pathways are associated with Thromboxane b2

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Thromboxane b2?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Thromboxane b2?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

What genes are associated with Thromboxane b2?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Thromboxane b2

Download all related citations
Per page 10 20 50 100 | Total 6367
Authors Title Published Journal PubMed Link
Winter M et al. Synthesis of thromboxane B2 in uraemia and the effects of dialysis. 1983 Thromb. Res. pmid:6868024
Stegmeier K et al. The pharmacological profile of the thromboxane A2 antagonist BM 13.177. A new anti-platelet and anti-thrombotic drug. 1984 Thromb. Res. pmid:6385334
Gerrard JM et al. Studies in patients with bleeding disorders show that platelet-vessel interaction is important for thromboxane formation in bleeding time wounds. 1990 Thromb. Res. pmid:2278038
Wang JP et al. Antiplatelet effect of capsaicin. 1984 Thromb. Res. pmid:6528310
Buchanan MR et al. The sex-related differences in aspirin pharmacokinetics in rabbits and man and its relationship to antiplatelet effects. 1983 Thromb. Res. pmid:6221436
Best LC et al. Mode of action of dipyridamole on human platelets. 1979 Thromb. Res. pmid:229583
Maderna P et al. Differential effects of oral administrations to human volunteers of acetylsalicylic acid, sodium salicylate and indomethacin on 12-hydroxyeicosatetraenoic acid formation by stimulated platelets. 1988 Thromb. Res. pmid:3194896
Li C et al. Aspirin response variability after major orthopedic surgery. 2012 Thromb. Res. pmid:22575418
Pirich C et al. Effects of fish oil supplementation on platelet survival and ex vivo platelet function in hypercholesterolemic patients. 1999 Thromb. Res. pmid:10588465
De Caterina R et al. Inhibition of platelet aggregation and thromboxane B2 production during aspirin treatment: dependence on the dose of the aggregating agent. 1985 Thromb. Res. pmid:3975876
Worthington RE and Fuller GC Dibutyryl cyclic guanosine monophosphate elevates bovine endothelial cell thromboxane production without affecting prostacyclin metabolism. 1984 Thromb. Res. pmid:6322377
Yamaguchi A et al. Effect of cetiedil on platelet aggregation and thromboxane synthesis. 1985 Thromb. Res. pmid:2986312
Mogensen F et al. Effect of specific thromboxane-synthetase inhibition on thromboxane and prostaglandin synthesis in stable angina induced by exercise test. 1985 Thromb. Res. pmid:4038824
Lukaszyk A et al. Does acute experimental pancreatitis affect blood platelet function? 1989 Thromb. Res. pmid:2524119
Best LC et al. The interrelationship between thromboxane biosynthesis, aggregation and 5-hydroxytryptamine secretion in human platelets in vitro. 1980 Thromb. Haemost. pmid:6773171
Greer IA et al. A comparative study of the effects of adrenoceptor antagonists on platelet aggregation and thromboxane generation. 1985 Thromb. Haemost. pmid:2867620
Joseph S et al. Effect of the polyamine-spermine on agonist-induced human platelet activation--specific inhibition of "aggregation-independent" events induced by thrombin, but not by collagen, thromboxane mimetic, phorbol ester or calcium ionophore. 1987 Thromb. Haemost. pmid:3110996
di Minno G et al. Effects of any epoxymethano stable analogue of prostaglandin endoperoxides (U-46619) on human platelets. 1981 Thromb. Haemost. pmid:6266066
Pampolina C and McNicol A Streptococcus sanguis-induced platelet activation involves two waves of tyrosine phosphorylation mediated by FcgammaRIIA and alphaIIbbeta3. 2005 Thromb. Haemost. pmid:15886812
Strano A et al. Platelet sensitivity to prostacyclin and thromboxane production in hyperlipidemic patients. 1982 Thromb. Haemost. pmid:6753232
Hansen JB et al. The effect of lipopolysaccharides (LPS) on generation of thromboxane A2 and thromboplastin activity in whole blood of males, females and females on oral contraceptives. 1989 Thromb. Haemost. pmid:2799762
Swartz SL and Moore TJ Effect of angiotensin II on collagen-induced platelet activation in normotensive subjects. 1990 Thromb. Haemost. pmid:2339363
Siess W et al. Stimulated platelet aggregation, thromboxane B2 formation and platelet sensitivity to prostacyclin - a critical evaluation. 1981 Thromb. Haemost. pmid:7025338
Watanabe J et al. Effect of vitamin E on platelet aggregation in diabetes mellitus. 1984 Thromb. Haemost. pmid:6495252
Matsumoto M et al. Thromboxane generation in patients with essential hypertension or cerebrovascular disease and effect of oral aspirin. 1980 Thromb. Haemost. pmid:7423441
Carter AJ et al. A comparison of human pulmonary arterial and venous prostacyclin and thromboxane synthesis--effect of a thromboxane synthase inhibitor. 1984 Thromb. Haemost. pmid:6377567
Spectre G et al. Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications. 2011 Thromb. Haemost. pmid:21800009
Honey AC et al. Effect of indomethacin and dazoxiben on intravascular platelet aggregation in the anaesthetized rabbit. 1986 Thromb. Haemost. pmid:3775692
Kyrle PA et al. Investigation of the interaction of blood platelets with the coagulation system at the site of plug formation in vivo in man--effect of low-dose aspirin. 1987 Thromb. Haemost. pmid:2954260
Krishnamurthi S et al. Effect of pyridoxal 5'-phosphate (PALP) on human platelet aggregation, dense granule release and thromboxane B2 generation--role of Schiff base formation. 1982 Thromb. Haemost. pmid:6891107
Essien EM et al. Blood changes and enhanced thromboxane and 6-keto prostaglandin F1 alpha production in experimental acute Plasmodium bergei infection in hamsters. 1984 Thromb. Haemost. pmid:6388013
Chen SL et al. Chlorobutanol, a preservative of desmopressin, inhibits human platelet aggregation and release in vitro. 1990 Thromb. Haemost. pmid:2096493
Martinuzzo ME et al. Antiphospholipid antibodies enhance thrombin-induced platelet activation and thromboxane formation. 1993 Thromb. Haemost. pmid:8115993
Kyrle PA et al. Thromboxane A2 and prostacyclin generation in the microvasculature of patients with atherosclerosis--effect of low-dose aspirin. 1989 Thromb. Haemost. pmid:2508252
Stratta P et al. Warning: platelet factor 4, beta-thromboglobulin and thromboxane in donor's plasma units. 1983 Thromb. Haemost. pmid:6189235
Larson MK et al. Effects of omega-3 acid ethyl esters and aspirin, alone and in combination, on platelet function in healthy subjects. 2008 Thromb. Haemost. pmid:18841286
Wang WJ and Huang TF A novel tetrameric venom protein, agglucetin from Agkistrodon acutus, acts as a glycoprotein Ib agonist. 2001 Thromb. Haemost. pmid:11686327
Jackson C et al. DN 9693: a phosphodiesterase inhibitor with a platelet membrane effect. 1989 Thromb. Haemost. pmid:2546286
Davì G et al. Increased thromboxane metabolites excretion in liver cirrhosis. 1998 Thromb. Haemost. pmid:9569186
Sheu JR et al. Mechanisms involved in the antiplatelet activity of Staphylococcus aureus lipoteichoic acid in human platelets. 2000 Thromb. Haemost. pmid:10823277
Crescente M et al. Gallic acid, a dietary polyphenolic component, blunts the inhibition of platelet COX-1 by aspirin: preliminary in-vitro findings. 2007 Thromb. Haemost. pmid:17549313
Landolfi R et al. Effects of unfractionated and low molecular weight heparins on platelet thromboxane biosynthesis "in vivo". 1994 Thromb. Haemost. pmid:7740468
Undas A et al. Lack of aspirin-induced decrease in thrombin formation in subjects resistant to aspirin. 2007 Thromb. Haemost. pmid:17549314
Perneby C et al. Dose- and time-dependent antiplatelet effects of aspirin. 2006 Thromb. Haemost. pmid:16601836
Eldor A et al. Effects of dipyrone on prostaglandin production by human platelets and cultured bovine aortic endothelial cells. 1983 Thromb. Haemost. pmid:6346571
Menys VC and Davies JA Selective inhibition of thromboxane synthetase with dazoxiben - basis of its inhibitory effect on platelet adhesion. 1983 Thromb. Haemost. pmid:6346575
Hampton KK et al. Coagulation, fibrinolytic and platelet function in patients on long-term therapy with aspirin 300 mg or 1,200 mg daily compared with placebo. 1990 Thromb. Haemost. pmid:2073296
Vejar M et al. Dissociation of platelet activation and spontaneous myocardial ischemia in unstable angina. 1990 Thromb. Haemost. pmid:2363117
Foo LC et al. Platelets of habitual smokers have reduced susceptibility to aggregating agent. 1991 Thromb. Haemost. pmid:2048056
Dragani A et al. Oxidative stress and platelet activation in subjects with moderate hyperhomocysteinaemia due to MTHFR 677 C→T polymorphism. 2012 Thromb. Haemost. pmid:22782530
Gordge MP et al. Platelet function and the bleeding time in progressive renal failure. 1988 Thromb. Haemost. pmid:3187950
D'Angelo A et al. Effect of des-amino-D-arginine vasopressin (DDAVP) on plasma levels of platelet and endothelial cell release products. 1983 Thromb. Haemost. pmid:6687766
Vezza R et al. Antivasoconstrictor and antiaggregatory activities of picotamide unrelated to thromboxane A2 antagonism. 1997 Thromb. Haemost. pmid:9408024
Lessiani G et al. Inflammation, oxidative stress and platelet activation in aspirin-treated critical limb ischaemia: beneficial effects of iloprost. 2011 Thromb. Haemost. pmid:21103664
Greer IA et al. Platelet activation in allergic asthma. 1985 Thromb. Haemost. pmid:2931855
Hohlfeld T et al. Antiplatelet effects of ticlopidine are reduced in experimental hypercholesterolemia. 1994 Thromb. Haemost. pmid:7513092
Han P et al. Verapamil and collagen-induced platelet reactions--evidence for a role for intracellular calcium in platelet activation. 1983 Thromb. Haemost. pmid:6415847
Guthikonda S et al. Increased platelet sensitivity among individuals with aspirin resistance - platelet aggregation to submaximal concentration of arachidonic acid predicts response to antiplatelet therapy. 2008 Thromb. Haemost. pmid:18612542
Gresele P et al. Platelet activation markers in patients with peripheral arterial disease--a prospective comparison of different platelet function tests. 1997 Thromb. Haemost. pmid:9423790
Naesh O et al. Platelet function in surgical stress. 1985 Thromb. Haemost. pmid:2935969
Davì G et al. The effect of two low doses of aspirin on whole blood thromboxane and prostacyclin generation in healthy subjects. 1983 Thromb. Haemost. pmid:6417815
Michelson AD et al. Reversible inhibition of human platelet activation by hypothermia in vivo and in vitro. 1994 Thromb. Haemost. pmid:7522354
Dale J et al. The effect of a thromboxane synthetase inhibitor, dazoxiben, and acetylsalicylic acid on platelet function and prostaglandin metabolism. 1983 Thromb. Haemost. pmid:6689091
Bar J et al. The regulation of platelet aggregation in vitro by interleukin-1beta and tumor necrosis factor-alpha: changes in pregnancy and in pre-eclampsia. 1997 Thromb. Haemost. pmid:9364994
Wang JS et al. Effect of strenuous arm exercise on oxidized-LDL-potentiated platelet activation in individuals with spinal cord injury. 2000 Thromb. Haemost. pmid:10928481
Subbiah MT et al. Studies of aggregation and thromboxane B2 synthesis in avian thrombocytes: comparison between atherosclerosis-susceptible and resistant breeds. 1980 Thromb. Haemost. pmid:7455983
Zahavi M et al. Abnormal typical pattern of platelet function and thromboxane generation in unstable angina. 1989 Thromb. Haemost. pmid:2531938
Halawani SH et al. Aspirin failure in patients presenting with acute cerebrovascular ischaemia. 2011 Thromb. Haemost. pmid:21544317
Connellan JM et al. Investigation of alternative mechanisms of collagen-induced platelet activation by using monoclonal antibodies to glycoprotein IIb-IIIa and fibrinogen. 1986 Thromb. Haemost. pmid:2940722
Patrono C et al. Characterization of biochemical and functional effects of antiplatelet drugs as a key to their clinical development. 1995 Thromb. Haemost. pmid:8578493
Cortellaro M et al. Transcoronary platelet thromboxane A2 formation without platelet trapping in patients with coronary stenosis-effect of sulphinpyrazone treatment. 1983 Thromb. Haemost. pmid:6665767
Falcon CR et al. The in vitro production of thromboxane B2 by platelets of diabetic patients is normal at physiological concentrations of ionized calcium. 1993 Thromb. Haemost. pmid:8259535
Larsen SB et al. Increased platelet aggregation and serum thromboxane levels in aspirin-treated patients with prior myocardial infarction. 2012 Thromb. Haemost. pmid:22534977
Fruzzetti F et al. Platelet-vessel wall interactions with third-generation oral contraceptives: no evidence of detrimental effects. 1999 Thromb. Haemost. pmid:10494782
Fimognari FL et al. Nocturnal rise of urinary thromboxane B 2 in patients with coronary artery disease. 2005 Thromb. Haemost. pmid:15735822
de Castellarnau C et al. Prostacyclin and thromboxane production by autogenous femoral veins grafted into the arterial circulation of the dog. 1989 Thromb. Haemost. pmid:2665174
Davì G et al. Demonstration of Rickettsia Conorii-induced coagulative and platelet activation in vivo in patients with Mediterranean spotted fever. 1995 Thromb. Haemost. pmid:8584998
Habib A et al. Increased expression of inducible cyclooxygenase-2 in human endothelial cells by antiphospholipid antibodies. 1995 Thromb. Haemost. pmid:8585020
Zahavi J and Zahavi M Enhanced platelet release reaction, shortened platelet survival time and increased platelet aggregation and plasma thromboxane B2 in chronic obstructive arterial disease. 1985 Thromb. Haemost. pmid:3158092
Evangelista V et al. Defibrotide inhibits platelet activation by cathepsin G released from stimulated polymorphonuclear leukocytes. 1992 Thromb. Haemost. pmid:1509406
Etulain J et al. Acidosis downregulates platelet haemostatic functions and promotes neutrophil proinflammatory responses mediated by platelets. 2012 Thromb. Haemost. pmid:22159527
Rocca B et al. Increased thromboxane biosynthesis in essential thrombocythemia. 1995 Thromb. Haemost. pmid:8607099
Pettinella C et al. Cyclooxygenase-1 haplotype C50T/A-842G does not affect platelet response to aspirin. 2009 Thromb. Haemost. pmid:19350112
Korbut R et al. On the mechanism of thrombolytic action of thromboxane synthetase inhibitors. 1987 Thromb. Haemost. pmid:3324381
Huang TF et al. Mechanism of action of a potent antiplatelet peptide, triflavin from Trimeresurus flavoviridis snake venom. 1991 Thromb. Haemost. pmid:1665595
Totani L et al. Prasugrel inhibits platelet-leukocyte interaction and reduces inflammatory markers in a model of endotoxic shock in the mouse. 2012 Thromb. Haemost. pmid:22436970
Véricel E et al. Moderate oral supplementation with docosahexaenoic acid improves platelet function and oxidative stress in type 2 diabetic patients. 2015 Thromb. Haemost. pmid:25832443
Kyrle PA et al. Evidence for an increased generation of prostacyclin in the microvasculature and an impairment of the platelet alpha-granule release in chronic renal failure. 1988 Thromb. Haemost. pmid:2975407
Hillbom M et al. Platelet thromboxane formation and bleeding time is influenced by ethanol withdrawal but not by cigarette smoking. 1985 Thromb. Haemost. pmid:4049313
Aoki T et al. Difference of (Ca2+)i movements in platelets stimulated by thrombin and TRAP: the involvement of alpha(IIb)beta3-mediated TXA2 synthesis. 1998 Thromb. Haemost. pmid:9657446
McMahon GS et al. Transient heparin-induced platelet activation linked to generation of platelet 12-lipoxygenase. Findings from a randomised controlled trial. 2013 Thromb. Haemost. pmid:23494053
Larsen SB et al. Reduced antiplatelet effect of aspirin is associated with low-grade inflammation in patients with coronary artery disease. 2013 Thromb. Haemost. pmid:23407706
Dotevall A et al. Cigarette smoking increases thromboxane A2 formation without affecting platelet survival in young healthy females. 1992 Thromb. Haemost. pmid:1455405
De Caterina R et al. Benefit/risk profile of combined antiplatelet therapy with ticlopidine and aspirin. 1991 Thromb. Haemost. pmid:1871711
De Caterina R et al. Equal antiplatelet effects of aspirin 50 or 324 mg/day in patients after acute myocardial infarction. 1985 Thromb. Haemost. pmid:4082090
Davì G et al. Influence of metabolic control on thromboxane biosynthesis and plasma plasminogen activator inhibitor type-1 in non-insulin-dependent diabetes mellitus. 1996 Thromb. Haemost. pmid:8819248
Ding YA et al. Potentiation of adrenaline-induced platelet aggregation by angiotensin II. 1985 Thromb. Haemost. pmid:4089801
Forastiero R et al. Anti-beta2 glycoprotein I antibodies and platelet activation in patients with antiphospholipid antibodies: association with increased excretion of platelet-derived thromboxane urinary metabolites. 1998 Thromb. Haemost. pmid:9459320
Carter AJ and Hanley SP The effect of platelet number and haematocrit on whole blood thromboxane synthesis. 1985 Thromb. Haemost. pmid:4024033
Butler KD et al. The effects of modulation of prostanoid metabolism on the thoracic platelet accumulation induced by intravenous administration of collagen in the guinea-pig. 1986 Thromb. Haemost. pmid:3105104